Article Versions Notes

Luque M, Cristóbal I, Sanz-Álvarez M, Santos A, Zazo S, Eroles P, Arpí O, Rovira A, Albanell J, Madoz-Gúrpide J, et al. CIP2A as a Key Regulator for AKT Phosphorylation Has Partial Impact Determining Clinical Outcome in Breast Cancer. Journal of Clinical Medicine. 2022; 11(6):1610. https://doi.org/10.3390/jcm11061610

Luque, Melani, Ion Cristóbal, Marta Sanz-Álvarez, Andrea Santos, Sandra Zazo, Pilar Eroles, Oriol Arpí, Ana Rovira, Joan Albanell, Juan Madoz-Gúrpide, and et al. 2022. "CIP2A as a Key Regulator for AKT Phosphorylation Has Partial Impact Determining Clinical Outcome in Breast Cancer" Journal of Clinical Medicine 11, no. 6: 1610. https://doi.org/10.3390/jcm11061610

Luque, M., Cristóbal, I., Sanz-Álvarez, M., Santos, A., Zazo, S., Eroles, P., Arpí, O., Rovira, A., Albanell, J., Madoz-Gúrpide, J., García-Foncillas, J., & Rojo, F. (2022). CIP2A as a Key Regulator for AKT Phosphorylation Has Partial Impact Determining Clinical Outcome in Breast Cancer. Journal of Clinical Medicine, 11(6), 1610. https://doi.org/10.3390/jcm11061610